<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030783</url>
  </required_header>
  <id_info>
    <org_study_id>AV-951-09-301</org_study_id>
    <nct_id>NCT01030783</nct_id>
  </id_info>
  <brief_title>A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma</brief_title>
  <acronym>TIVO-1</acronym>
  <official_title>A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm
      trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed
      to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health
      outcome measurements of tivozanib and sorafenib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm
      trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed
      to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health
      outcome measurements of tivozanib and sorafenib.

      Subjects will be randomized (1:1) to treatment with tivozanib or sorafenib and stratified by
      geographic region (North America/Western Europe, Central/Eastern Europe, or rest of the
      world); number of prior treatments (0 or 1); and number of metastatic sites/organs involved
      (1 or ≥ 2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks.</time_frame>
    <description>Progression-Free Survival (PFS) is defined as the time from randomization to first documentation of objective tumor progression (progressive disease) or death due to any reasons whichever comes first. Disease progression per RECIST 1.0 criteria is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</measure>
    <time_frame>Date of randomization to date of death</time_frame>
    <description>Overall survival (OS) is defined as the time from the date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive. Subjects lacking data beyond randomization will have their survival times censored on the date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</measure>
    <time_frame>Every 8 weeks from date of randomization until disease progression</time_frame>
    <description>Objective response rate (ORR) is defined as the percentage of subjects who have at least a 30% reduction in the sum of diameters per RECIST (Version 1.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</measure>
    <time_frame>Assessed every 8 weeks from date of randomization until date of progression</time_frame>
    <description>Duration of response (DR) is defined as the time from the first documentation of objective tumor response to the first documentation of tumor progression per RECIST 1.0 or to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Tivozanib and Sorafenib</measure>
    <time_frame>From start of treatment therapy to completion of treatment therapy, an average of 11 months</time_frame>
    <description>Dose reductions and interruptions were allowed for subjects taking tivozanib or sorafenib. Any modification of study drug administration, and the reason for such action, was clearly noted on the subject's eCRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib</measure>
    <time_frame>At Day 1 of each 28 day cycle throughout the course of the study, for an average of 11 months per subject</time_frame>
    <description>The Disease Related Symptom Scale of the Functional Assessment of Cancer Therapy - Advanced Kidney Cancer Symptom Index (FKSI-DRS) measured kidney specific symptoms on a 0-36 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The Functional Assessment of Cancer Therapy-General (FACT-G) measured general wellbeing scored on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The European Quality of Life-5 Dimensions (EQ-5D) measured patient health related quality of life scored on a 0-1 scale, with 0 being worse health state and 1 being perfect health state. The European Quality of Life-5 Dimensions Visual Analog Scales (EQ-5D VAS) measured patient health related quality of life on a visual analog scale from 0 to 100, with 0 being the worst and 100 being the best. These scales were self-administered by patients at the start of the visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Serum Concentrations) of Tivozanib</measure>
    <time_frame>Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28</time_frame>
    <description>Samples for tivozanib serum concentrations will be collected at the following time points: Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28. The serum concentrations of tivozanib were tabulated for individual subjects and summarized by nominal time using standard descriptive statistics (concentrations presented in ng/mL).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">517</enrollment>
  <condition>Advanced Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>tivozanib (AV-951)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tivozanib (AV-951)</intervention_name>
    <description>Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
    <arm_group_label>tivozanib (AV-951)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
    <arm_group_label>sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18-years of age.

          2. Subjects with recurrent or metastatic RCC.

          3. Subjects must have undergone prior nephrectomy (complete or partial) for excision of
             the primary tumor.

          4. Histologically or cytologically confirmed RCC with a clear cell component (subjects
             with pure papillary cell tumor or other non-clear cell histologies, including
             collecting duct, medullary, chromophobe, mixed tumor containing predominantly
             sarcomatoid cells, and unclassified RCC are excluded).

          5. Measurable disease per the RECIST criteria Version 1.0.

          6. Treatment naïve subjects or subjects who have received no more than one prior systemic
             treatment (immunotherapy, including interferon-alfa or interleukin-2 based therapy,
             chemotherapy, hormonal therapy or an investigational agent) for metastatic RCC.
             Postoperative or adjuvant systemic therapy will not be counted as a prior therapy
             unless recurrence is detected within 6 months of completion of treatment, in which
             case it will be counted as a prior therapy for metastatic disease.

          7. ECOG performance status of 0 or 1, and life expectancy ≥ 3 months.

          8. If female and of childbearing potential, documentation of negative pregnancy test
             prior to enrollment.

          9. Ability to give written informed consent and comply with protocol requirements.

        Exclusion Criteria:

          1. Any prior VEGF-directed therapy including VEGF antibody (eg, bevacizumab), VEGF
             receptor tyrosine kinase inhibitor (eg, sunitinib, sorafenib, axitinib, pazopanib,
             etc.), VEGF trap (eg, aflibercept), or any other agent or investigational agent
             targeting the VEGF pathway.

          2. Any prior therapy with an agent targeting the mTOR pathway (eg, temsirolimus,
             everolimus, etc)

          3. Primary CNS malignancies or CNS metastases; subjects with previously treated brain
             metastasis will be allowed if the brain metastasis have been stable without steroid
             treatment for at least 3 months following prior treatment (radiotherapy or surgery).

          4. Any hematologic abnormalities (as noted in the protocol).

          5. Any serum chemistry abnormalities (as noted in the protocol).

          6. Significant cardiovascular disease.

          7. Non-healing wound, bone fracture, or skin ulcer.

          8. Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other
             gastrointestinal condition with increased risk of perforation; history of abdominal
             fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior
             to administration of first dose of study drug.

          9. Serious/active infection or infection requiring parenteral antibiotics.

         10. Inadequate recovery from any prior surgical procedure or major surgical procedure
             within 4 weeks prior to administration of first dose of study drug.

         11. Significant thromboembolic or vascular disorders within 6 months prior to
             administration of first dose of study drug.

         12. Significant bleeding disorders within 6 months prior to administration of first dose
             of study drug.

         13. Currently active second primary malignancy, including hematologic malignancies
             (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers,
             non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular
             carcinoma in situ of the breast. Subjects are not considered to have a currently
             active malignancy if they have completed anti-cancer therapy and have been disease
             free for &gt;2 years.

         14. Pregnant or lactating females.

         15. History of genetic or acquired immune suppression disease such as HIV; subjects on
             immune suppressive therapy for organ transplant.

         16. Life-threatening illness or organ system dysfunction compromising safety evaluation.

         17. Requirement for hemodialysis or peritoneal dialysis.

         18. Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that
             severely affects the absorption of tivozanib or sorafenib, major resection of the
             stomach or small bowel, or gastric bypass procedure.

         19. Psychiatric disorder or altered mental status precluding informed consent or necessary
             testing.

         20. Sexually active pre-menopausal female subjects (and female partners of male subjects)
             must use adequate contraceptive measures, while on study and for 50 days after the
             last dose of study drug. Sexually active male subjects must use adequate contraceptive
             measures, while on study for at least 90 days after the last dose of drug. All fertile
             male and female subjects and their partners must agree to use a highly effective
             method of contraception (including their partner). Effective birth control includes
             (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods
             are male or female condoms, diaphragms, and spermicides (creams or gels that contain a
             chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be
             affected by cytochrome P450 interactions, and are not considered effective for this
             study.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. Motzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 185</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 180</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 184</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 182</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 186</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 187</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Sante Fe</city>
        <zip>3077</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 403</name>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 404</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 400</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 401</name>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 402</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 110</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 121</name>
      <address>
        <city>La Reina</city>
        <state>Santiago De Chile</state>
        <zip>7510009</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 122</name>
      <address>
        <city>Santiago</city>
        <zip>8320000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 123</name>
      <address>
        <city>Temuco</city>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 411</name>
      <address>
        <city>Prague 8</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 130</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 133</name>
      <address>
        <city>Saint Herblain Cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 423</name>
      <address>
        <city>Budapest</city>
        <zip>H-1108</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 421</name>
      <address>
        <city>Kaposvár</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 422</name>
      <address>
        <city>Pécs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 424</name>
      <address>
        <city>Szombathely</city>
        <zip>H-9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 157</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 190</name>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <zip>801505</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 156</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 151</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 153</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 159</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 191</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 155</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 152</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 158</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 150</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 154</name>
      <address>
        <city>Delhi</city>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 160</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 161</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 162</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 432</name>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 434</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 431</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 435</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 433</name>
      <address>
        <city>Poznan</city>
        <zip>61-878</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 430</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 436</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 444</name>
      <address>
        <city>Brasov</city>
        <zip>500085</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 441</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 440</name>
      <address>
        <city>Bucharest</city>
        <zip>041345</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 443</name>
      <address>
        <city>Bucharest</city>
        <zip>050659</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 442</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 459</name>
      <address>
        <city>Ufa</city>
        <state>Republic Of Bashkortostan</state>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 451</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 455</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 468</name>
      <address>
        <city>Ioshkar Ola</city>
        <zip>424037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 452</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 454</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 453</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 458</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 460</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 461</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 462</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 450</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 456</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 467</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 463</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 457</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 466</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 465</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 464</name>
      <address>
        <city>Yaroslavi</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 480</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 481</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 482</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 483</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 484</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 491</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 492</name>
      <address>
        <city>Dniproperovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 498</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 493</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 496</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 490</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 494</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 497</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 495</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 170</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 173</name>
      <address>
        <city>Ipswich</city>
        <zip>IP4 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 172</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.aveopharma.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <results_first_submitted>April 30, 2019</results_first_submitted>
  <results_first_submitted_qc>October 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2019</results_first_posted>
  <disposition_first_submitted>January 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2013</disposition_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tivozanib (AV-951)</title>
          <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sorafenib</title>
          <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Tivozanib (AV-951)</title>
          <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sorafenib</title>
          <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="260"/>
            <count group_id="B2" value="257"/>
            <count group_id="B3" value="517"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="23" upper_limit="83"/>
                    <measurement group_id="B2" value="59" lower_limit="23" upper_limit="85"/>
                    <measurement group_id="B3" value="59" lower_limit="23" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib</title>
        <description>Progression-Free Survival (PFS) is defined as the time from randomization to first documentation of objective tumor progression (progressive disease) or death due to any reasons whichever comes first. Disease progression per RECIST 1.0 criteria is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks.</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (AV-951)</title>
            <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib</title>
          <description>Progression-Free Survival (PFS) is defined as the time from randomization to first documentation of objective tumor progression (progressive disease) or death due to any reasons whichever comes first. Disease progression per RECIST 1.0 criteria is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="9.3" upper_limit="14.7"/>
                    <measurement group_id="O2" value="9.1" lower_limit="7.3" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</title>
        <description>Overall survival (OS) is defined as the time from the date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive. Subjects lacking data beyond randomization will have their survival times censored on the date of randomization.</description>
        <time_frame>Date of randomization to date of death</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (AV-951)</title>
            <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</title>
          <description>Overall survival (OS) is defined as the time from the date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive. Subjects lacking data beyond randomization will have their survival times censored on the date of randomization.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" lower_limit="22.5" upper_limit="33.0"/>
                    <measurement group_id="O2" value="30.8" lower_limit="28.4" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</title>
        <description>Objective response rate (ORR) is defined as the percentage of subjects who have at least a 30% reduction in the sum of diameters per RECIST (Version 1.0).</description>
        <time_frame>Every 8 weeks from date of randomization until disease progression</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (AV-951)</title>
            <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</title>
          <description>Objective response rate (ORR) is defined as the percentage of subjects who have at least a 30% reduction in the sum of diameters per RECIST (Version 1.0).</description>
          <population>ITT Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" lower_limit="27.4" upper_limit="39.2"/>
                    <measurement group_id="O2" value="23.3" lower_limit="18.3" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</title>
        <description>Duration of response (DR) is defined as the time from the first documentation of objective tumor response to the first documentation of tumor progression per RECIST 1.0 or to death due to any cause.</description>
        <time_frame>Assessed every 8 weeks from date of randomization until date of progression</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (AV-951)</title>
            <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib</title>
          <description>Duration of response (DR) is defined as the time from the first documentation of objective tumor response to the first documentation of tumor progression per RECIST 1.0 or to death due to any cause.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="12.9" upper_limit="NA">The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event.</measurement>
                    <measurement group_id="O2" value="12.9" lower_limit="11.0" upper_limit="NA">The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Tivozanib and Sorafenib</title>
        <description>Dose reductions and interruptions were allowed for subjects taking tivozanib or sorafenib. Any modification of study drug administration, and the reason for such action, was clearly noted on the subject's eCRF.</description>
        <time_frame>From start of treatment therapy to completion of treatment therapy, an average of 11 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (AV-951)</title>
            <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Tivozanib and Sorafenib</title>
          <description>Dose reductions and interruptions were allowed for subjects taking tivozanib or sorafenib. Any modification of study drug administration, and the reason for such action, was clearly noted on the subject's eCRF.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reasons for Dose Interruptions - Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reasons for Dose Reductions - Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib</title>
        <description>The Disease Related Symptom Scale of the Functional Assessment of Cancer Therapy - Advanced Kidney Cancer Symptom Index (FKSI-DRS) measured kidney specific symptoms on a 0-36 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The Functional Assessment of Cancer Therapy-General (FACT-G) measured general wellbeing scored on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The European Quality of Life-5 Dimensions (EQ-5D) measured patient health related quality of life scored on a 0-1 scale, with 0 being worse health state and 1 being perfect health state. The European Quality of Life-5 Dimensions Visual Analog Scales (EQ-5D VAS) measured patient health related quality of life on a visual analog scale from 0 to 100, with 0 being the worst and 100 being the best. These scales were self-administered by patients at the start of the visit.</description>
        <time_frame>At Day 1 of each 28 day cycle throughout the course of the study, for an average of 11 months per subject</time_frame>
        <population>ITT Population, excluding questionnaires that were not analyzable</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (AV-951)</title>
            <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib</title>
          <description>The Disease Related Symptom Scale of the Functional Assessment of Cancer Therapy - Advanced Kidney Cancer Symptom Index (FKSI-DRS) measured kidney specific symptoms on a 0-36 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The Functional Assessment of Cancer Therapy-General (FACT-G) measured general wellbeing scored on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The European Quality of Life-5 Dimensions (EQ-5D) measured patient health related quality of life scored on a 0-1 scale, with 0 being worse health state and 1 being perfect health state. The European Quality of Life-5 Dimensions Visual Analog Scales (EQ-5D VAS) measured patient health related quality of life on a visual analog scale from 0 to 100, with 0 being the worst and 100 being the best. These scales were self-administered by patients at the start of the visit.</description>
          <population>ITT Population, excluding questionnaires that were not analyzable</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FACT-G Total Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.16" spread="0.785"/>
                    <measurement group_id="O2" value="73.05" spread="0.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FKSI-DRS Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.71" spread="0.227"/>
                    <measurement group_id="O2" value="28.58" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D Weighted Health State Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.014"/>
                    <measurement group_id="O2" value="0.66" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D VAS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                    <count group_id="O2" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.50" spread="0.826"/>
                    <measurement group_id="O2" value="68.49" spread="0.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Serum Concentrations) of Tivozanib</title>
        <description>Samples for tivozanib serum concentrations will be collected at the following time points: Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28. The serum concentrations of tivozanib were tabulated for individual subjects and summarized by nominal time using standard descriptive statistics (concentrations presented in ng/mL).</description>
        <time_frame>Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28</time_frame>
        <population>All patients who had taken at least 1 dose of tivozanib and who had at least one measurable concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib (AV-951)</title>
            <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Serum Concentrations) of Tivozanib</title>
          <description>Samples for tivozanib serum concentrations will be collected at the following time points: Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28. The serum concentrations of tivozanib were tabulated for individual subjects and summarized by nominal time using standard descriptive statistics (concentrations presented in ng/mL).</description>
          <population>All patients who had taken at least 1 dose of tivozanib and who had at least one measurable concentration value.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.05" lower_limit="65.0" upper_limit="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.87" lower_limit="28.0" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 22-28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.37" lower_limit="49.8" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to last dose plus 30 days, approximately 1 year on average</time_frame>
      <desc>Safety Population</desc>
      <group_list>
        <group group_id="E1">
          <title>Tivozanib (AV-951)</title>
          <description>tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Sorafenib</title>
          <description>Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Salivary gland mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Malignant urinary tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Metastases to ovary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>AVEO Pharmaceuticals, Inc.</organization>
      <phone>617-588-1960</phone>
      <email>Clinical@aveooncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

